The prescription market for the hypertension drug "Losartan" has shrunk significantly. It is analyzed that a large number of prescription gaps occurred due to detection of excess impurities at the end of last year. According to UBIST, a pharmaceutical research agency, on the 2nd, the outpatient prescription amount of Losartan-containing drugs in the first quarter was 60 billion won, down 24.4% from the same period last year-on-

The prescription market for Losartan drugs rose 20.7% in four years from 65.8 billion won in the first quarter of 2017 to 79.5 billion won in the first quarter of last year, showing a stable upward trend every year. In the third quarter of last year, it formed a market size of 81.2